At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy
In Brief
A Phase 2 clinical trial evaluating Placebo and IXT-m200 for Methamphetamine-dependence and Methamphetamine Abuse. Completed, enrolled 77 participants across 2 sites.
Detailed Summary
This study evaluates the ability of IXT-m200 to change methamphetamine concentrations in blood and alter the way methamphetamine feels. Participants will receive either placebo, a low or high dose of IXT-m200, in addition to methamphetamine challenge doses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMethamphetamine-dependence, Methamphetamine Abuse
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartMay 2018
Primary CompletionNov 2020
Study CompletionMar 2021
TodayJul 2026
First PostedNov 8, 2017
Enrollment StartMay 3, 2018
Primary CompletionNov 23, 2020
Study CompletionMar 9, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.7 years ago
Interventions
Placebodrug
Normal saline
IXT-m200drug
IXT-m200 is an anti-methamphetamine monoclonal antibody